175 related articles for article (PubMed ID: 29807526)
1. Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD.
Aliagas E; Muñoz-Esquerre M; Cuevas E; Careta O; Huertas D; López-Sánchez M; Escobar I; Dorca J; Santos S
Respir Res; 2018 May; 19(1):103. PubMed ID: 29807526
[TBL] [Abstract][Full Text] [Related]
2. NTPDase1/CD39 and aberrant purinergic signalling in the pathogenesis of COPD.
Lazar Z; Müllner N; Lucattelli M; Ayata CK; Cicko S; Yegutkin GG; De Cunto G; Müller T; Meyer A; Hossfeld M; Sorichter S; Horvath I; Virchow CJ; Robson SC; Lungarella G; Idzko M
Eur Respir J; 2016 Jan; 47(1):254-63. PubMed ID: 26541524
[TBL] [Abstract][Full Text] [Related]
3. Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine).
Muñoz-Esquerre M; Aliagas E; López-Sánchez M; Escobar I; Huertas D; Penín R; Dorca J; Santos S
PLoS One; 2017; 12(5):e0177218. PubMed ID: 28545096
[TBL] [Abstract][Full Text] [Related]
4. Suppression of endothelial CD39/ENTPD1 is associated with pulmonary vascular remodeling in pulmonary arterial hypertension.
Helenius MH; Vattulainen S; Orcholski M; Aho J; Komulainen A; Taimen P; Wang L; de Jesus Perez VA; Koskenvuo JW; Alastalo TP
Am J Physiol Lung Cell Mol Physiol; 2015 May; 308(10):L1046-57. PubMed ID: 25820525
[TBL] [Abstract][Full Text] [Related]
5. Purinergic dysregulation in pulmonary hypertension.
Visovatti SH; Hyman MC; Goonewardena SN; Anyanwu AC; Kanthi Y; Robichaud P; Wang J; Petrovic-Djergovic D; Rattan R; Burant CF; Pinsky DJ
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H286-98. PubMed ID: 27208163
[TBL] [Abstract][Full Text] [Related]
6. [Interleukin-17 expression and significance in normal lung function smokers and chronic obstructive pulmonary disease patients].
Zhang JQ; Lao QF; Chu SY; Bai J; Zhong XN
Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1431-5. PubMed ID: 20646637
[TBL] [Abstract][Full Text] [Related]
7. Imbalance in the Expression of Genes Associated with Purinergic Signalling in the Lung and Systemic Arteries of COPD Patients.
Careta O; Cuevas E; Muñoz-Esquerre M; López-Sánchez M; Pascual-González Y; Dorca J; Aliagas E; Santos S
Sci Rep; 2019 Feb; 9(1):2796. PubMed ID: 30808894
[TBL] [Abstract][Full Text] [Related]
8. [The changes and significance of interleukin-16 and CXC chemokine receptor 3 expression in pulmonary artery of smokers with chronic obstructive pulmonary disease].
Wan P; Zhong XN; He ZY; Zhang JQ; Liu GN; Lao QF
Zhonghua Nei Ke Za Zhi; 2009 Oct; 48(10):841-5. PubMed ID: 20079227
[TBL] [Abstract][Full Text] [Related]
9. Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema.
Reimann S; Fink L; Wilhelm J; Hoffmann J; Bednorz M; Seimetz M; Dessureault I; Troesser R; Ghanim B; Klepetko W; Seeger W; Weissmann N; Kwapiszewska G
Respir Res; 2015 Oct; 16():127. PubMed ID: 26483185
[TBL] [Abstract][Full Text] [Related]
10. Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer.
Schmid S; Kübler M; Korcan Ayata C; Lazar Z; Haager B; Hoßfeld M; Meyer A; Cicko S; Elze M; Wiesemann S; Zissel G; Passlick B; Idzko M
Lung Cancer; 2015 Dec; 90(3):516-21. PubMed ID: 26505137
[TBL] [Abstract][Full Text] [Related]
11. Apyrase protects against allergic airway inflammation by decreasing the chemotactic migration of dendritic cells in mice.
Li P; Cao J; Chen Y; Wang W; Yang J
Int J Mol Med; 2014 Jul; 34(1):269-75. PubMed ID: 24804736
[TBL] [Abstract][Full Text] [Related]
12. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease.
Kranenburg AR; de Boer WI; Alagappan VK; Sterk PJ; Sharma HS
Thorax; 2005 Feb; 60(2):106-13. PubMed ID: 15681497
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Adenosine 5'-Triphosphate in Obstructive Airway Diseases.
Pelleg A; Schulman ES; Barnes PJ
Chest; 2016 Oct; 150(4):908-915. PubMed ID: 27568579
[TBL] [Abstract][Full Text] [Related]
14. Possible role of Krüppel-like factor 5 in the remodeling of small airways and pulmonary vessels in chronic obstructive pulmonary disease.
Abe K; Sugiura H; Hashimoto Y; Ichikawa T; Koarai A; Yamada M; Numakura T; Onodera K; Tanaka R; Sato K; Yanagisawa S; Okazaki T; Tamada T; Kikuchi T; Ichinose M
Respir Res; 2016 Jan; 17():7. PubMed ID: 26792671
[TBL] [Abstract][Full Text] [Related]
15. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells.
Imai M; Kaczmarek E; Koziak K; Sévigny J; Goepfert C; Guckelberger O; Csizmadia E; Schulte Am Esch J; Robson SC
Biochemistry; 1999 Oct; 38(41):13473-9. PubMed ID: 10521254
[TBL] [Abstract][Full Text] [Related]
16. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease.
Lommatzsch M; Cicko S; Müller T; Lucattelli M; Bratke K; Stoll P; Grimm M; Dürk T; Zissel G; Ferrari D; Di Virgilio F; Sorichter S; Lungarella G; Virchow JC; Idzko M
Am J Respir Crit Care Med; 2010 May; 181(9):928-34. PubMed ID: 20093639
[TBL] [Abstract][Full Text] [Related]
17. Characterization of pulmonary vascular remodeling and MicroRNA-126-targets in COPD-pulmonary hypertension.
Goel K; Egersdorf N; Gill A; Cao D; Collum SD; Jyothula SS; Huang HJ; Sauler M; Lee PJ; Majka S; Karmouty-Quintana H; Petrache I
Respir Res; 2022 Dec; 23(1):349. PubMed ID: 36522710
[TBL] [Abstract][Full Text] [Related]
18. Klotho expression is reduced in COPD airway epithelial cells: effects on inflammation and oxidant injury.
Gao W; Yuan C; Zhang J; Li L; Yu L; Wiegman CH; Barnes PJ; Adcock IM; Huang M; Yao X
Clin Sci (Lond); 2015 Dec; 129(12):1011-23. PubMed ID: 26201096
[TBL] [Abstract][Full Text] [Related]
19. Systemic and Pulmonary Vascular Remodelling in Chronic Obstructive Pulmonary Disease.
Muñoz-Esquerre M; López-Sánchez M; Escobar I; Huertas D; Penín R; Molina-Molina M; Manresa F; Dorca J; Santos S
PLoS One; 2016; 11(4):e0152987. PubMed ID: 27046203
[TBL] [Abstract][Full Text] [Related]
20. The expression level of ecto-NTP diphosphohydrolase1/CD39 modulates exocytotic and ischemic release of neurotransmitters in a cellular model of sympathetic neurons.
Corti F; Olson KE; Marcus AJ; Levi R
J Pharmacol Exp Ther; 2011 May; 337(2):524-32. PubMed ID: 21325440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
